Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand-valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR as necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Ethylene glycol, glycols, and related compounds/
Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if necessary. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 ml/kg up to 200 ml of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool. Administer activated charcoal ... . /Ethylene glycol, glycols, and related compounds/
Groups of 3 female rats/time interval were administered single doses of 14C - labeled BPG in corn oil ranging from 18-22 mg/rat either orally (via gavage) or dermally (applied to a 2 cm x 3 cm area of the back and held in place for 6 hours). Following dosing, the rats were housed in metabolism cages for collection of urine, feces, CO2, and tissues for 6, 24, or 96 hours. Based on data from 96 hours collection period, amount of radioactivity absorbed following oral and dermal dosing was 58.7% and 12%, respectively. Following the oral administration, the amount of radioactivity found as percent of administered dose of BPG was 35.2%, 41%, 3.3%, and 20.2% in urine, feces, tissues, and expired CO2, respectively. Following the dermal administration, the amount of radioactivity found as percent of dose was 2.8%, 1.4%, 6.1%, and1.4% in urine, feces, tissues, and expired CO2, respectively.
1.周国泰,化学危险品安全技术全书,化学工业出版社,1997 2.国家环保局有毒化学品管理办公室、北京化工研究院合编,化学品毒性法规环境数据手册,中国环境科学出版社.1992 3.Canadian Centre for Occupational Health and Safety,CHEMINFO Database.1998 4.Canadian Centre for Occupational Health and Safety, RTECS Database, 1989
[EN] PHOTOCHROMIC AND ELECTROCHROMIC DIARYLETHENE COMPOUNDS WITH IMPROVED PHOTOSTABILITY AND SOLUBILITY<br/>[FR] COMPOSÉS DIARYLÉTHÈNE PHOTOCHROMIQUES ET ÉLECTROCHROMES PRÉSENTANT UNE PHOTOSTABILITÉ ET UNE SOLUBILITÉ AMÉLIORÉES
申请人:SWITCH MAT INC
公开号:WO2020198868A1
公开(公告)日:2020-10-08
A diarylethene compound reversibly convertible under photochromic and electrochromic conditions between a ring-open isomer of Formula (1A) and a ring-closed isomer of Formula (IB) wherein R5 is a substituted phenyl ring and Re is a substituted thiophene ring is provided. The photochromic-electrochromic diarylethene compound of Formula (1A)/(1B) have improved photochromic, electrochromic or photochromic and electrochromic properties, and is useful to provide variation of the light transmission properties of optical filters. The compound also possesses improved solubility making it suitable for incorporation in commercial products..
Method for manufacturing pigment dispersed liquid, and pigment dispersed liquid, and ink for ink-jet printer recording using said pigment dispersed liquid
申请人:SEIKO EPSON CORPORATION
公开号:US20020088375A1
公开(公告)日:2002-07-11
A method for manufacturing a pigment dispersed liquid, comprising at least:
Step A of introducing a hydrophilic dispersibility-imparting group directly and/or via another atomic group to the surface of pigment particles;
Step B of dispersing the pigment obtained in Step A in an aqueous medium; and
Step C of conducting refining treatment of the dispersed liquid obtained in Step B.
Method of Fabricating Glycol Monoalkyl Ether Acetate Using Acidic Ionic Liquid Catalyst
申请人:Wu Jung-Chung
公开号:US20110184207A1
公开(公告)日:2011-07-28
A new method for fabricating glycol monoalkyl ether acetate (GMAEA) is provided. A Bronsted acidic ionic liquid is used. After some reactions, two layers of materials are formed. A product of GMAEA is obtained at the upper layer. The lower layer is the ionic liquid. Thus, the ionic liquid is reusable for re-fabricating the product. And, furthermore, waste acid is reduced.
ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF
申请人:Meng Charles Q.
公开号:US20140142114A1
公开(公告)日:2014-05-22
The present invention relates to novel anthelmintic compounds of formula (I) below:
wherein
Y and Z are independently a bicyclic carbocyclic or a bicyclic heterocyclic group, or one of Y or Z is a bicyclic carbocyclic or a bicyclic heterocyclic group and the other of Y or Z is alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, heterocyclyl or heteroaryl, and variables X
1
, X
2
, X
3
, X
4
, X
5
, X
6
, X
7
and X
8
are as defined herein. The invention also provides for veterinary compositions comprising the anthelmintic compounds of the invention, and their uses for the treatment and prevention of parasitic infections in animals.
[EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
申请人:AVISTA PHARMA SOLUTIONS INC
公开号:WO2020160075A1
公开(公告)日:2020-08-06
The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the disclosure have activity as prostaglandin EP4 receptor antagonists, and are useful in the treatment or alleviation of pain and inflammation and other inflammation-associated disorders, such as arthritis, treating or preventing disorders or medical conditions selected from pain, inflammatory diseases and the like. Also described herein are methods of treating pain by administering the compounds of the disclosure, which are EP4 receptor antagonists.